Podcasts about Kario

Ukraina dronais apšaudė Maskvą. Ar tai ką nors keis kare?Puolime Rusijos Kursko srityje dalyvaujantis Ukrainos karys teigia, kad viena iš sėkmingo puolimo priežasčių – netikėtumas. Kario interviu LRT žurnalistui Benui Gerdžiūnui.Švietimo mokslo ir sporto ministerija žada svarstyti, ar moksleiviams verta mokytis birželį.Lietuva kviečia Jungtines Valstijas prisidėti prie rotacinio oro gynybos modelio regione.Šiandien Vilniuje susitiko Baltijos šalių viešbučių ir restoranų asociacijų vadovai. Susitikime svarstyta ekonominė situacija šalyse ir spręsta, ar dėl mokesčių lengvatų nereikėtų kovoti protestuojant.Seimo Nacionalinio saugumo ir gynybos, Aplinkos apsaugos ir Kaimo reikalų komitetų nariai susitiko su Tauragės krašto gyventojais dėl naujojo karinio poligono statybų, kurioms ir toliau gana aktyviai priešinamasi. Žmonės sako bijantys triukšmo ir taršos. Poligonų statybos, jei tam pritartų Seimas, būtų pradėtos šį rudenį.Ved. Liepa Želnienė

On this edition of the On The Pony Express Podcast, Billy Embody breaks down the addition of Oregon transfer guard Kario Oquendo for SMU Basketball, 4-star QB Keelon Russell visiting Texas and resetting SMU Football recruiting ahead of May. Head to StatusJet.com to learn more about the official presenting sponsor of the On The Pony Express Podcast. Use code PonyUpACC or mention On The Pony Express for a discount on a round trip flip booked with Status Jet. Status Jet is more than just a private jet charter company. They offer a personal touch in every aspect of your business and travel. Whether you are looking for charter flights, searching for the perfect aircraft to buy, or interested in selling a plane, experience a new level of luxury with Status Jet. At Status Jet, their goal is simple: to not only meet your unique needs but to exceed them. Status Jet offers the safest, finest aircraft in the luxury private jet charter industry, coupled with an unparalleled level of service. With a number of domestic and international destinations, as well as custom destinations tailored to your needs, they are prepared to fly above your expectations. At Status Jet, they don't just take you from point A to point B—they bring fun and fascination back to the flying experience. Use promo code PONY for FREE SHIPPING on your order from EpochWines.com! Head to EpochWines.com to join the Epoch Wine Club, a customizable club for those eager to automatically access new releases of Epoch wines two times a year. If the club isn't for you, buy individual bottles online! Get custom engraving, gift packaging, bundles and more! Want to buy the official game ball of SMU Football? Check out BigGameUSA.com or click HERE to see the official game ball for Preston Stone and the Mustangs! Use promo code "BEON3" for 10% off your order + FREE shipping! Use the code on SMU balls or any available ball on BigGameUSA.com! SUBSCRIBE to On The Pony Express YouTube by clicking HERE! Want more coverage of SMU Basketball and SMU Football, including the inside scoop on the team and recruiting? Subscribe to On The Pony Express by going here to join for $1 for your first month: https://www.on3.com/teams/smu-mustangs/join/  Follow our social media channels: Instagram: https://www.instagram.com/on3smu/ Twitter: https://twitter.com/smuon3 Facebook: https://www.facebook.com/OnThePonyExpress Learn more about your ad choices. Visit megaphone.fm/adchoices

LRT GIRDI gavo užklausą, kurioje teigiama, kad moteris, dirbanti pagal individualios veiklos sutartį, tvarkingai mokėjo privalomojo socialinio draudimo įmokas, tačiau dabar sulaukė pranešimo, kad permokėjo pusantro tūkstančio eurų ir neaišku, kodėl. Moteris sako, kad nenori apgaudinėti valstybės, todėl bando išsiaiškinti iš kur atsirado permoka, tačiau į Sodrą prisiskambinti neįmanoma. Tuo metu kiti gyventojai sulaukė pranešimų, kad kaip tik sumokėjo per mažai mokesčio. Kas čia yra nutikę?Ukrainai šiandien bus perduota dalis už „Radarom” akcijos metu surinktus pinigus nupirktų saugaus kario paketų, kuriuos sudaro naktinio matymo monokuliaras, lazerinis taikiklis ir individualus antidronas.Penktadienis prieš Velykas paprastai ta diena, kai prekybos centrai sulaukia daugiausia pirkėjų. Tiesa, į madą grįžtant kiaušinių dažymui svogūnų lukštais, pirkėjai sako, kad lukštų gauti sudėtinga, o pardavėjai pastebi, kad kai kurie pirkėjai tiesiog nulupa nuo svogūnų lukštus. Pastebimas ir baltų kiaušinių trūkumas. Klausimas klausytojams - ar pasigendate baltų kiaušinių ir svogūnų lukštų?Lygiai prieš 20 metų tapo NATO nare. Šiuo metu NATO atsidūrė ir ties didžiausia Europos saugumo grėsme, ir ties vienu didžiausių egzistencinių išbandymų. Didelių vidinių krizių organizacija turėjo ir anksčiau ir gana didelių.Diskutuojant, kur rasti papildomų lėšų šalies gynybai, dalis verslo atstovų teigia, kad sutiktų mokėti didesnius mokesčius. Kaip tai galėtų būti įgyvendinta? – apie tai „Verslo laike”.Po terooro išpuolio Maskvoje,už kurį atsakomybę prisiėmė teroristų organizacijos islamo valstybė atšaka, Europos šalių dėmesio centre ir vėl atsidūrė terorizmo grėsmė. Prancūzija, kurioje šią vasarą vyks Olimpinės žaidynės, paskelbė aukščiausią saugumo pavojaus lygį. Daugiau apie saugumo grėsmes Prancūzijoje rubrikoje „Naujienų žemėlapis”.Ved. Rūta Kupetytė

Ukrainiečiams šiandien bus perduoti pirmieji už akcijoje Radarom suaukotus pinigus nupirkti saugaus kario rinkiniai.Su Rusija besiribojančiame Charkivo regione Ukrainoje jau antrą savaitę darbuojasi keturi Lietuvos medikai. Lietuviai gydytojai lanko žmones tokiose vietovėse, į kurias bijo važiuoti kitų šalių medikai. Hoptivkos kaimas nuo Rusijos pasienio yra nutolęs vos 3 kilometrus, jame likę 60 gyventojų.Seimas svarsto, ar leisti bibliotekoms dovanoti nurašytas knygas. Pasak kultūros ministro, šiuo metu įstatymai tokios galimybės nenumato, o nebereikalingas knygas bibliotekoms tampa paprasčiau išmesti nei ieškoti naujo savininko. Visuomenės dėmesio prieš porą metų buvo sulaukusi situacija, kai prie Lietuvos sveikatos mokslų universiteto bendrabučio kieme statybiniame konteineryje rasta išmesta daugybė senovinių knygų. Ar reikėtų leisti bibliotekoms dovanoti nurašytas knygas?Rita Juškytė įkvepia žmones su negalia ne tik šokti vežimėlyje, rasti savyje pasitikėjimo ir drąsos, bet ir toliau aktyviai gyventi, dirbti ir jaustis reikalingais. Apie tai – „Versle iš širdies”.„Turiu abejonių, ar Europa gali apsiginti pati, be JAV“, - Miuncheno saugumo konferencijoje sakė Užsienio reikalų ministras Gabrielius Landsbergis. Šios diskusijos kilo dėl JAV pozicijos ir ryžto ginti Europą po lapkritį vyksiančių rinkimų. Ar įmanoma Europai gintis be Jungtinių Valstijų?Valstybės grėsmių ataskaitose minima pedagogė E.Kanaitė iki šiol neatleista iš Vilniaus darželio „Svaja“ direktoriaus pavaduotojų, nes turi nedarbingumo pažymėjimą. Tačiau oficialiai būdama nedarbinga ji dalyvauja pasitarimuose dėl tautinių mažumų mokyklų likimo. „Sodros” atstovė sako, kad turint nedarbingumą dirbti griežtai draudžiama, šį atvejį ketinama tirti, jeigu faktai pasitvirtins, Kanaitė gali netekti nedarbingumo išmokų.

Ramy Essam blev internationellt känd från protesterna på Tahrirtorget i Kario under den arabiska våren 2011. Ensam på scen med en gitarr blev hans protestsånger mot regimen en symbol för de ungas kamp. Men musiken var också orsaken till att han greps och torterades. Lyssna på alla avsnitt i Sveriges Radio Play. Nu är det snart tio år sedan han kom som fristadsmusiker till Malmö.Nyligen släpptes hans senaste album ”Metgharabiin” - främlingskap - en platta som handlar just om ett konstnärskap i exil, ibland väldigt långt hemifrån. P1 Kultur har träffat honom.Reporter: Esfar AhmadProgramledare: Lisa WallProducent: Felicia Frithiof

▼ Follow Nicksher Music: » Spotify Playlist: https://open.spotify.com/playlist/4dI7kNNcEGQ8MSGLYVh39T?si=Zg1yjJAHTASjK7xa5S-Lew » SoundCloud: https://soundcloud.com/nickshermusic » YouTube: https://www.youtube.com/channel/UCcTF27v-cpxlBfLdQODpFTw » Facebook: https://www.facebook.com/groups/1706975586219784/ » Beatport: https://beatport.com/label/nicksher-music/57468 » VK: https://vk.com/club123650463 » Instagram: https://www.instagram.com/nickshermusic/ --- ▼ Follow Shadi Kario: SoundCloud: https://soundcloud.com/shadikario Facebook: https://www.facebook.com/shady.kario

What did we learn about the Bulldogs in the top-ranked showdown last week? We dive into all the details of Georgia's big win and return to No. 1 in the CFP rankings. And we have to discuss Stetson Bennett's phone calls and what the super-senior had to say about the number of calls he received the night before the game. We also welcome in UGA hoops highlight reel guard Kario Oquendo to discuss the new regime for the Bulldogs, how he feels about the Bulldogs' season-opening win and where the program goes under Mike White. He also gives us his No. 1 highlight as a Bulldog, his tight relationship with UGA football players and about Dominique Wilkins swinging by practice.  Tune in and subscribe today!

**Steve Vimto's Eclectic Sessions Replay On traxfm.org. This Week Vimto Gave Us Eclectic/Indie Dance/RNB/HipHop/House/Remixes/Future House Beauties From Kokoroko, Lisa Shaw, Kario, Speelburg, Halo & Maiya Feat Atjazz, Just Kiddin & DiRTY RADiO, Greentea Peng, Mark Capanni, Rick James, Rozalla's "Everybody's Free" (Paul Oakenfold Mix), The Smiths, Orange Juice & More Catch Steve Vimto's Eclectic Sessions Every Thursday From 5PM UK Time The Station: traxfm.org #traxfm #soul #funk #danceclassics #house #indie #hiphop #boogie #eclectic #RnB #remixes Listen Live Here Via The Trax FM Player: chat.traxfm.org/player/index.html Mixcloud LIVE :mixcloud.com/live/traxfm Free Trax FM Android App: play.google.com/store/apps/det...mradio.ba.a6bcb The Trax FM Facebook Page : facebook.com/original103.3 Trax FM Live On Hear This: hearthis.at/k8bdngt4/live Tunerr: tunerr.co/radio/Trax-FM Tune In Radio : tunein.com/radio/Trax-FM-s225176 OnLine Radio Box: onlineradiobox.com/uk/trax/?cs...cs=uk.traxRadio Radio Deck: radiodeck.com/radio/5a09e2de87...7e3370db06d44dc Radio.Net: traxfmlondon.radio.net Stream Radio : streema.com/radios/Trax_FM..The_Originals Live Online Radio: liveonlineradio.net/english/tr...ax-fm-103-3.htm**

Jungtinės Valstijos ir Europa skelbia vienybę Rusijos atžvilgiu, tvyrant įtampai dėl Ukrainos.Auga visuomenės pasitikėjimas kariuomene, kario profesija, palankiau vertinama ir narystė NATO, rodo Krašto apsaugos ministerijos užsakymu atlikta apklausa.Kainas stebinčio portalo pricer.lt duomenimis, sausio mėnesį Lietuvoje brango pigiausių maisto produktų krepšelis. Vertinant konkrečiais skaičiais, sausį, palyginti su gruodžiu, šių produktų vidutinis krepšelis brango beveik 4-iais procentais.Finansų ministrė teigia, kad Lietuva neketina sekti Lenkijos pavyzdžiu, šiai šaliai nuo vasario pusmečiui įvedant nulinį pridėtinės vertės mokesčio tarifą maisto produktams.Institucijos stengiasi gerinti migrantų apgyvendinimo sąlygas, sako Valstybės sienos apsaugos tarnybos vadas Rustamas Liubajevas.Vaikų dienos centrai skundžiasi skurstantys dėl smarkiai išaugusių mokesčių.Turine įvyko oficiali Eurovizijos burtų traukimo ceremonija, kurioje 36 šalys padalintos į du pusfinalius.Ved. Paulius Šironas

Au programme de l'émission du 03 novembre 2021 : Pour cette seconde semaine de vacances, le programme est surtout littéraire, avec la rediffusion de l'interview de l'illustratrice et autrice Kotimi diffusé la première fois en octobre 2020. La nouveauté discographique - chronique de Véronique Soulé - c'est au début - Panique dans la forêt – Weepers Circus, livre CD illustré par Clotilde Perrin – Gallimard jeunesse, septembre 2021, 25 € Dans ce conte musical, joyeux et farfelu, le groupe rock Weepers Circus revisite avec beaucoup d'humour le motif archi connu des enfants qui se perdent dans une forêt sombre et maléfique : des dialogues truculents, Tchéky Kario impeccable en narrateur, une douzaine de chansons à l'image des dialogues, un rien barrées, avec quelques artistes complices - Yves Jamait, Kent, Sanseverino, Oldefaf, Léopoldine HH ou Antonia de Reidinger. Pas de temps mort dans ce conte musical d'une soixantaine de minutes, mené tambour battant, et aux arrangements musicaux particulièrement toniques ! Le mercredi, c'est lecture – chronique d'Augustine et d'Othilie – c'est vers 09 mn Augustine et Othilie, 13 ans, présentent ensemble un roman de circonstance : - Comment tu m'as fait mourir, de Gilles Abier, 240 p., Slalom, octobre 2020 Livres – chronique de Véronique Soulé – c'est vers 13 mn - Ça gazouille, de Constantin Kaïtéris, illustré par Kotimi, Møtus, septembre 2021 Un recueil d'une trentaine de poésies, souvent brèves, célèbrent les oiseaux des plus connus aux plus rares, de façon joyeuse, simple, avec un joli travail sur la langue, les sonorités ou les jeux de mots. De son pinceau trempé dans l'encre de chine noir, ou bien au fusain, rehaussé de couleurs bleues déclinée dans différentes teintes, Kotimi a mis en scène, de façon vive et malicieuse, ces oiseaux dans toute leur variété. Livres - interview de Kotimi– c'est vers 18 mn Il y a tout juste un an, l'illustratrice et autrice Kotimi répondait à nos questions sur son album Momoko, une enfance japonaise, qui venait de paraitre, ainsi que sur sa démarche artistique. La parution récente de Ça gazouille nous donne l'occasion de rediffuser cet entretien (première diffusion : octobre 2020). Grands livres pour petites personnes - chronique de Elsa Gounot - c'est vers 51 mn  - Le Petit Robot de bois et la Princesse bûche, de Tom Gauld, traduit de l'anglais par Rosalind Elland-Goldsmith, L'école des loisirs, septembre 2021 "Dans un royaume heureux, les enfants du couple royal ont été créés par une inventrice pour le petit robot de bois et par une sorcière pour la princesse bûche. Celle-ci se transforme en bûche de bois toutes les nuits dès qu'elle s'endort, jusqu'à ce que son frère vienne la réveiller par une formule magique chaque matin. Un jour, une servante la voit endormie, en état de bûche, et la jette par la fenêtre." Lecture - par Lionel Chenail - c'est vers 7O mn  - Le fils du professeur, de Luc Chomirat, La manufacture des livres, septembre 2021 On a écouté -[Le début de] Panique dans la forêt – Weepers Circus – livre-disque, Gallimard jeunesse, septembre 2021 -Duo piano et rossignol progné – Daniel Goyone – Chante rossignol chante – CD, Naïve, 2002 -Tous ensemble – Zut – 20/20 – CD, 2020 -Tranquille – Tony Melvil et Usmar – Manque à l'appel – CD, Compagnie illimitée, 2019

Bienvenido de nuevo al podcast “Made 4 Gamers”. En este episodio Reely y Punisher están discutiendo sobre temas tal como ubisoft quiere crear su propio Battle royale estilo de Warzone, Warzone Tendra un mapa nuevo en la proxima temporada, traemos una entrevista al streamer y creador de contenido "Kario Gaming" y mas.

This episode is sponsored by Davwill Consulting. Emotional agility? Yep, it's needed more now than ever. Let's chat! Click Here Adi Mazor Kario, Innovation and Value creation expert, Invincible Innovation Founder. Adi Is One Of The Most Sought After Product Innovation Strategists Alive Today. Known for her ability to take creative business ideas and turn them into massive revenue, she leverages her proven strategies to create leading-edge business growth for the world's most forward-thinking business leaders. She has worked with the likes of IBM, Intel, Google, and Waze — along with literally hundreds of startups in Israel, the “Startup Nation,” and played a crucial role in the Google Accelerator for 8 years — and now she has turned her eyes toward Europe. Her last creation is a book called “Innovating Through Chaos: a proven formula to launching unbeatable products during uncertain times”. Adi works with a team of worldwide professionals with a background in entrepreneurship, Innovation, strategy and design. Her mission is to show ANY business (including yours!) how to innovate their way out of ANY challenge and create unbeatable products — ESPECIALLY during uncertain times. In fact, the biggest lesson Adi has learned in her time as a design and innovation strategist for today's fastest-growing companies is that change is your BEST opportunity for growth. And she would love to show you how.  https://invincibleinnovation.com/ https://invincibleinnovation.com/book/ https://www.linkedin.com/in/adimazorkario/

Please join editorialist Padma Kaul and Associate Editor Karol Watson as they discuss the original research article "Preterm Delivery and Long-Term Risk of Stroke in Women: A National Cohort and Cosibling Study" and the editorial "Pregnancy as Oracle: What it Augurs for Women's Health." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast, summary and backstage pass to the journal and its editors. We're your co-hosts, I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Oh Greg, today's feature paper is really important. It's about preterm delivery and the long-term risk of stroke in women. A very, very important cardiovascular risk factor that we don't talk about. This is important data from the national cohort and co-sibling study. So hang on, look out for it. But first, how would you take us through some of your spotted original papers? Dr. Greg Hundley: So Carolyn, my first paper comes to us from Dr. Guido Claessen from University Hospitals in Leuven. Exertional intolerance, Carolyn, is a limiting and often crippling symptom in patients with chronic thromboembolic pulmonary hypertension, and traditionally, the etiology has been attributed to central factors, including ventilation, perfusion mismatch, increased pulmonary vascular resistance and right heart dysfunction and uncoupling. So pulmonary endarterectomy and balloon pulmonary angioplasty provides substantial improvement of functional status and hemodynamics. However, despite normalization of these pulmonary hemodynamics, exercise capacity often does not return to age-predicted values. So by systemically evaluating the oxygen pathway, these authors aim to elucidate the causes of functional limitations of chronic thromboembolic pulmonary hypertension patients before and after these pulmonary vascular interventional procedures. Dr. Carolyn Lam: So very interesting. Tell us more, what did they find, Greg? Dr. Greg Hundley: Yeah, well Carolyn, they utilize cardiovascular magnetic resonance, as you know, one of my big interests, but guess what? They also did it with exercise and simultaneous invasive hemodynamic monitoring. The authors in doing so, sought to quantify the steps of the oxygen transport cascade from the mouth to the mitochondria in patients with this pulmonary hypertension. So they had 20 subjects with pulmonary hypertension and they compared those to 10 healthy individuals. Furthermore Carolyn, the authors evaluated the effect of pulmonary vascular intervention procedures, both endarterectomy or balloon angioplasty, on the individual components of the cascade in 10 of those 20 individuals. Dr. Greg Hundley: So what did they find? They found that in this chronic thromboembolic pulmonary hypertension condition, these patients, they have significant impairments of all steps in the oxygen utilization cascade, resulting in markedly impaired exercise capacity, the thick equation uncoupled. And pulmonary vascular interventions increased, peak VO2, by partly correcting the oxygen delivery, but having no impact on abnormalities in peripheral oxygen extraction. Dr. Greg Hundley: So Carolyn, this suggests that the current interventions only partially address patient's limitations and that additional therapies may improve functional capacity, such as improvement in skeletal muscle function and metabolism. So maybe one of your faves, cardiac rehab, perhaps could work on some of those peripheral factors in these patients. So, really interesting, very well accomplished study. Dr. Carolyn Lam: Nice, elegant and clinically impactful. Very nice. Well, the next paper is the same. We know that prenatal detection has benefits for infants with hypoplastic left heart syndrome and transposition of the great arteries. Well, this next paper describes the largest multicenter study to evaluate whether social economic quartile, public insurance, race or ethnicity, rural residence and distance from the residence are associated with the prenatal detection of critical congenital heart diseases in North America. This study is from Dr. Krishnan from Children's National Medical Center in Washington, DC and colleagues. Basically, what they found was that lower socioeconomic position, Hispanic ethnicity, and rural residence were all associated with decrease prenatal detection rates of hypoplastic left heart syndrome and transposition of the great arteries. Dr. Greg Hundley: Wow Carolyn, so social determinants of health, interesting. So how do we, as clinicians, apply these results? Dr. Carolyn Lam: Well, clinicians can use the findings of the study to focus efforts on improving overall prenatal detection rates for congenital heart disease. They can specifically improve health equity in prenatal detection and timing of prenatal detection by improving linkages between tertiary care centers and these populations and regions that were identified in this study. Dr. Greg Hundley: Very nice Carolyn. Well, I'm going to turn to the world of aortic aneurysms and this next paper comes to us from Dr. Maria Mittelbrun from Centro de Biología Molecular Severo Ochoa. Carolyn, it involves Marfan syndrome, which you know, is an autosomal dominant disorder of the connective tissue caused by mutations in the FBN1 gene, encoding a large glycoprotein in the extracellular called fibrillin one. The major complication, again as you know, of this connective disorder is the risk to develop thoracic aortic aneurysms. To date, no effective pharmacological therapies have been identified for the management of thoracic aortic disease and the only options capable of preventing aneurysm rupture are surgery. So here, the authors studied the role of mitochondrial dysfunction in the progression of thoracic aortic aneurysm dilation, and mitochondrial boosting strategies as a potential treatment to manage these aneurysms. Dr. Carolyn Lam: Wow, that's really fascinating. So what did they find? Dr. Greg Hundley: So Carolyn, just like in circulation, these wonderful translational basic science studies, the research here by these authors was performed in both mice and in patient samples from Marfans patients. So mitochondrial function of vascular smooth muscle cells was found to be controlled by the extracellular matrix and drive the development of aortic aneurysm in the Marfan syndrome. Interestingly, restoring mitochondrial metabolism with the NAD precursors nicotinamide riboside rapidly reversed aortic aneurysm in the fibrillin positive mice. Thus Carolyn, the clinical implications are that by potentially targeting vascular metabolism, a new available therapeutic strategy for managing aortic aneurysms associated with these genetic disorders, such as Marfan syndrome, may become available. Really interesting new development in the world of managing aortic aneurysm dilation in patients with Marfan syndrome. Dr. Carolyn Lam: Oh my goodness, that would be paradigm shifting. Wow, hope that's going to be pursued further. Well, this next one is from the preclinical world and this study really uncovered a metabolic transcriptional axis that explains how dividing cells coordinate metabolism with gene regulation in pulmonary arterial hypertension. So this is from Dr. Rabinovitch and colleagues from Stanford University School of Medicine who applied RNA sequencing to pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension with and without a BMPR2 mutation compared to control pulmonary artery smooth muscle cells, basically to uncover genes required for their heightened proliferation and glycolytic metabolism. The assessment of differentially expressed genes establish metabolism as a major pathway. The most highly up-regulated metabolic gene was aldehyde dehydrogenase family 1 member 3, an enzyme previously linked to glycolysis and proliferation in cancer cells and systemic vascular smooth muscle cells, but now demonstrated in pulmonary arterial hypertension. Isn't that cool? Dr. Carolyn Lam: The findings were basically like this, an increase in this particular aldehyde dehydrogenase family 1 member 3, underlined the heightened proliferation and glycolysis of pulmonary artery smooth muscle cells in patients with both idiopathic and hereditary pulmonary artery hypertension, while promoting survival of their endothelial cells under stress. The authors further uncovered the way this molecule interacted with genetic factors in doing so and then finally demonstrated that transgenic mice with the deletion in smooth muscle cells did not develop chronic hypoxia-induced pulmonary hypertension. Dr. Greg Hundley: Wow Carolyn, really new, inventive material from the world of basic science. So what's the take-home message? Dr. Carolyn Lam: So these findings really suggest that selectively disrupting the pivotal role of aldehyde dehydrogenase family 1 member 3 in pulmonary artery hypertension smooth muscle cells, note that was smooth muscle cells, not the endothelial cells, may be a important therapeutic consideration in patients. Dr. Greg Hundley: Very nice. Dr. Carolyn Lam: So Greg, let me tell you about some other articles in today's issue. There's an exchange of letters between Drs. Pengo and Kario 00:10:36 regarding the article Nighttime Blood Pressure Phenotype And Cardiovascular Prognosis, A Practitioner-based Nationwide JAMP Study. Dr. Greg Hundley: Great Carolyn, well also in the mail bag, we have a perspective piece from Professor Chang entitled Trial By Wildfire, The Need To Expand The Framework Of Environmental Determinants Of Cardiovascular Health From Climate Change To Planetary Health. Also, there's a primer from Professor Miano entitled The Fate And State Of Smooth Muscle Cells And Atherosclerosis. Then lastly, we have another article from the world of basic science, a research letter from Dr. Ieda entitled Overexpression Of GATA4, MEF2C and TBX5 Generates Induced Cardiomyocytes Via Direct Reprogramming And Rare Fusion In The Heart. Well, Carolyn, how about we get to the world of preterm delivery and onto that feature article? Dr. Carolyn Lam: I'm there already, let's go. Dr. Greg Hundley: Well, listeners. Now we are turning to our feature discussion and we're so excited today to have with us our editorialist for this article, Dr. Padma Kaul and our own associate editor, Dr. Karol Watson and we'll be discussing today, a paper related to preterm delivery and long-term risk of stroke in women. Padma, I'd like to start with you. Describe for us a little bit, the context for this study, and then what were the authors' study population and study design? Dr. Padma Kaul: So Greg, this is a study, which is a retrospective cohort study from Sweden and they looked at women who had given birth over a pretty long period of time, from 1973 to 2015. In over two million women, they looked at the association between preterm birth and the long-term development of stroke in the mothers. It's a really interesting study. What they did find is that preterm birth was associated with a higher hazard ratio for stroke, over 48 million person years of follow-up. The authors also did an interesting co-sibling analysis to supplement what the overall primary analysis. This was by looking at a subset of women who had at least one sibling in the cohort. The point of that was to assure that the association between preterm birth and stroke risk remained, even after you account for familial or genetic environmental factors. They do find that it was demonstrated even in the subset. Dr. Greg Hundley: Very nice, just a couple quick clarifying points. Were these ischemic strokes, were they hemorrhagic strokes? And then give me a little bit of definition. How did they define preterm? Dr. Padma Kaul: So preterm was in less than 37 weeks of gestation, and they looked at both hemorrhagic as well as ischemic strokes in the women. So they did an overall stroke endpoint as well as looked at whether these two types of strokes, whether the relationship stayed. Dr. Greg Hundley: And was there any particular age at which these strokes occurred? Dr. Padma Kaul: That's an excellent point. As I told you, that the time period of the study is pretty long. So they did stratify the follow-up period into 10 year segments, and they found that higher risk in the early part of the 10 and the 10 to 20 time periods. It stayed in the latter periods as well, but it was more so associated with a higher hazard in the early time periods, the 10 and the 20. Dr. Greg Hundley: Thank you so much, Padma. Well now listeners, we're going to turn to our associate editor, Dr. Karol Watson from UCLA. Karol, I know working on the editorial board at Circulation, you see many papers come across your desk. What attracted you to this particular manuscript? And how would you put the results from this study in the context of other studies that have really evaluated women's health in this situation? Dr. Karol Watson: That's a fabulous question. I think really so many great manuscripts come in and there are important features of many of them, but this one caught my eye for a couple of reasons. It was so incredibly well done. This is a huge, huge cohort of over two million women and it's from Sweden, where they keep really exquisite records, so we had so much data on this population. So we really got to know all about these soliton deliveries in Sweden, over a 40 year period. So the great cohort that was really well characterized, the really long follow-up. I love the co-sibling analysis that they talked about, they really did control for so many things, shared familial factors, shared genetic factors, covariates. So they just did a fabulous study. Dr. Karol Watson: So, in the whole realm of women's health, we are understanding that pregnancy is a great window into a woman's vascular future. So we now know so many things, we know that preterm delivery is amongst those pregnancy outcomes that we have to look for. So we have to look for pregnancy-induced hypertension, gestational diabetes, but also preterm delivery and pregnancy loss. So all of these things are telling us that a woman's vascular system is under stress and we have to do things to make sure they have good outcomes, because we know they're at greater risk. Dr. Greg Hundley: Very nice. So as leading experts in the era, Padma first to you, and then I'll come back to Karol. Padma, tell us, what do you think is the next area of research that needs to be explored in this topic area? Dr. Padma Kaul: I think that this is an observational study. So one of the things we have to recognize is how do we add to the evidence that this study has provided us? That I think, is to see if in other cohorts, similar pregnancy birth cohorts with longitudinal data, whether we observe the same patterns that we ever observed in Sweden. Sweden is actually quite unique in terms of the makeup of the population and these are historical trends. We do know that the characteristics of the mothers who are giving birth are changing over time. Women are delaying childbirth, they are getting heavier, they may have preexisting conditions. So I think to keep monitoring the health of the mothers and pregnancy factors is what is needed to move the field forward. Dr. Greg Hundley: Very nice, and Karol? Karol, would you like to add anything? Dr. Karol Watson: Yeah, I agree completely with what Padma says. The beauty of the Swedish cohort is how well characterized it is, but one of the limitations is it's a fairly homogenous cohort. So I would love to see similar data in other racial or ethnic groups. We'd also like to see, again, as Padma said, this is observational cohort study, so we don't know truly the causal validy here, although this is a really good study to identify this trend. I would love to think of ways why this might be, we really don't have a good handle on the pathobiology. We can surmise some things endothelial dysfunction, et cetera, but we just don't know for sure. The other thing I'd like to think of is ways we might address mitigating risk. If this truly is a risk factor, how are we going to help these women have better vascular outcomes. But again, a great study to start all these questions. Dr. Greg Hundley: Well, thank you Karol and Padma and listeners. We certainly want to thank both Drs. Kaul and Watson for their time today and also the author group under the direction of Dr. Casey Crump for submitting this article to us at Circulation reporting on this large cohort of women from Sweden, identifying a preterm delivery and long-term risk of both ischemic and hemorrhagic stroke. Dr. Greg Hundley: Well, on behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week on the run. This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit ahajournals.org.  

This time a special episode- a talk with Adi Mazor Kario (usually on the interviewer seat), about startups, the startup nation, and innovation. This talk is part of the Innov8rs Unconference, May 21. We will discuss: - Invincible Innovation product formula - Why innovation is important today, more than ever? - What could we learn from the startup nation? Thanks for watching Invincible innovation LIVE A Show About The Future Of People With Tech I'm Adi Mazor Kario, #1 Product Innovation & Value Creation Expert, Invincible Innovation. I'd love to hear your feedback and thoughts in the comments below! If you want to know more about me and my work: https://www.invincibleinnovation.com/​ Hope you'll enjoy the talk! #startup #startupnation #innovation #leadership #management #invincibleinnovation #openinnovation #cocreation #covid19 #opportunities #valuecreation

On this episode of the Idea to Value podcast, we speak with Adi Mazor Kario, innovation strategy and design expert and author of Innovating through Chaos. See the full episode at https://wp.me/p6pllj-1vg We talk about how innovation drives the Israeli economy, where this culture of innovation comes from, and how companies can continue innovating during chaos. Topics covered in this episode: 00:01:30 - Adi's story starting with product design and getting fired from her job while holding her baby 00:05:00 - Why Israel is such a hotbed of innovation, and why their people are so confident 00:08:30 - The Invincible Innovation formula, and how it is based on practicality 00:11:30 - Why open-mindedness is so important for innovation, and getting used to uncertainty 00:14:00 - Innovating through Chaos Links mentioned in this episode: Innovating through Chaos book: https://amzn.to/3odZyON Adi's Linkedin profile: https://www.linkedin.com/in/adimazorkario/ Invincible Innovation: https://invincibleinnovation.com/ Bonus: This episode was made possible by our premium innovation and creativity training. Take your innovation and creativity capabilities to the next level by investing in yourself now, at https://www.ideatovalue.com/all-access-pass-insider-secrets/ * Subscribe on iTunes to the Idea to Value Podcast: https://itunes.apple.com/gb/podcast/idea-to-value-creativity-innovation/id1199964981?mt=2 * Subscribe on Spotify to the Idea to Value Podcast: https://open.spotify.com/show/4x1kANUSv7UJoCJ8GavUrN  * Subscribe on Stitcher to the Idea to Value Podcast: http://www.stitcher.com/s?fid=129437&refid=stpr * Subscribe on Google Podcasts to the Idea to Value Podcast: https://podcasts.google.com/?feed=aHR0cHM6Ly9pZGVhdG92YWx1ZS5saWJzeW4uY29tL3Jzcw  Want to rapidly validate new ideas and innovative products and GROW your online business? These are the tools I actually use to run my online businesses (and you can too): * The best email management and campaigns system: ActiveCampaign (Free Trial) http://www.activecampaign.com/?_r=M17NLG2X  * Best value web hosting: BlueHost WordPress http://www.activecampaign.com/?_r=M17NLG2X  * Landing pages, Sales Pages and Lead collection: LeadPages (Free Trial) http://leadpages.pxf.io/c/1385771/390538/5673  * Sharing & List building: Sumo (Free) https://sumo.com/?src=partner_ideatovalue  * Payments, Shopping Cart, affiliate management and Upsell generator: ThriveCart https://improvides--checkout.thrivecart.com/thrivecart-standard-account/  * Video Webinars for sales: WebinarJam and Everwebinar ($1 Trial) https://nickskillicorn.krtra.com/t/lwIBaKzMP1oQ  * Membership for protecting content: Membermouse (Free Trial) http://affiliates.membermouse.com/idevaffiliate.php?id=735  * eLearning System for students: WP Courseware https://flyplugins.com/?fly=293  * Video Editing: Techsmith Camtasia http://techsmith.z6rjha.net/vvGPv  I have used all of the above products myself to build IdeatoValue and Improvides, which is why I can confidently recommend them. I may also receive affiliate payments for any business I bring to them using the links above. Copyright https://www.ideatovalue.com

Creativity is structured. It may sound a contradiction of terms, but when you really think of it, it does make sense. We live in a structured world and creative energy does not float amorphously through it without some structure to contain it – to allow us to focus in it. Before artists can create, then need to put up a structure that will allow us to work in their creative space. This episode's guest, Kario Salem, knows this to be true from his decades of experience as an artist. Kario is a respected pluralist, actor, screenwriter and musician. In this conversation with with David Jensen and Cecily Chambers, Kario shares his creative journey in acting, music and writing, and the lessons he accumulated over those colorful years. Listen and partake of his valuable insights on ambition and rebellion, being present, willful destruction of the ego and his honest thoughts on the country's political atmosphere in the midst of the COVID-19 pandemic, racial unrest and social upheaval.

This week’s episode features author Kazuomi Kario and Associate Editor Wanpen Vongpatanasin as they discuss the article "Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP (Japan Ambulatory Blood Pressure Monitoring Prospective) Study." TRANSCRIPT BELOW: Dr Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast, summary, and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley: And I'm Dr Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Carolyn, when is the best time to check your blood pressure if you have a home monitoring device? Morning? Afternoon? Nighttime? And what do those nighttime fluctuations infer? Well, we'll hear a lot more in our feature discussion today, but first let's grab a cup of coffee and jump into some of the other papers in the issue. I'm going to start first this week, and my first paper comes from Dr Joe Wu at Stanford University. Carolyn, a quiz. Are all endothelial cells alike? Dr Carolyn Lam: Jeez, Greg. Okay, I'm going to hedge. I bet a lot of them share similarities, but there may be some differences. Dr Greg Hundley: Yes, Carolyn. Dr Wu and his associates perform a series of elegant experiments involving mice, and they found that certain tissue-specific endothelial cells cluster strongly by tissue, like those in the liver or the brain, whereas others from, for example, adipose tissue or the heart have considerable transcriptomic overlap with endothelial cells from other tissues. They identified novel markers of tissue-specific endothelial cells and signaling pathways that may be involved in maintaining their identity, and sex was a considerable source of heterogeneity in the endothelial transcriptome. In addition, they found that markers of heart and lung endothelial cells in mice were conserved in human fetal heart and lung endothelial cells and identified potential angiocrine interactions between tissue-specific endothelial cells and other cell types by analyzing ligand and receptor expression patterns. Dr Carolyn Lam: So interesting, Greg. You especially had me at sex differences. So, what's the take home message? Dr Greg Hundley: Right, Carolyn. So this group discovered a series of transcriptional networks that maintain endothelial cell heterogeneity, and that angiocrine and functional relationships exist between tissue-specific endothelial cells. These findings open the door for future studies that can manipulate these pathways and perhaps modify processes, like atherosclerosis, that impact the endothelium. Dr Carolyn Lam: Wow, that's cool, Greg. Well, from your paper, I'm going to a mechanistic paper too, and the next study really aimed to define cardiac fibroblasts' heterogeneity during ventricular remodeling, as well as the underlying mechanisms that regulate their function, so important questions here. And co-corresponding authors, Drs Prósper and Lara-Astiaso from Clinica Universidad de Navarra in Pamplona in Spain, as well as Dr Lindner from Maine Medical Center Research Institute in Scarborough, Maine in the U.S., and their co-authors, basically characterized cardiac fibroblasts after myocardial infarction using a whole host of very novel techniques like single-cell and bulk RNA sequencing, ATAC sequencing, and functional assays. Swine and patient samples were studied using bulk RNA sequencing. Dr Greg Hundley: Very intriguing. What did they find? Dr Carolyn Lam: They identified and characterized a unique cardiac fibroblast subpopulation that emerged after myocardial infarction in mice. These activated fibroblasts exhibited a clear profibrotic signature expressing high levels of collagen triple helix repeat containing 1 and localized into the scar. Moreover, the absence of this regulator resulted in pronounced lethality due to ventricular rupture. Finally, a population of cardiac fibroblasts with a similar transcriptome was identified in a swine model of myocardial infarction, as well as in heart tissues from patients with myocardial infarction and dilated cardiomyopathy. Dr Greg Hundley: Ah, so important information on how fibroblasts start the scar formation after infarction. So, Carolyn what's the take home message here for this research? Dr Carolyn Lam: Well, this paper really provides important information on cardiac fibroblast heterogeneity, their dynamics during the course of myocardial infarction, and the authors also redefine the cardiac fibroblasts that respond to cardiac injury and participate in myocardial remodeling. This study identifies collagen triple helix repeat containing 1 as a novel regulator of the healing scar process, and as a target for future translational studies. Dr Greg Hundley: Great, Carolyn. You're doing such a great job. This is an issue for double quiz. Have you ever heard of treatments for hypertension incorporating Chinese herbal formula gastrodia-uncaria granules? Dr Carolyn Lam: What? Are you trying to speak Chinese, Greg? Dr Greg Hundley: Yeah (affirmative) Okay. Dr Carolyn Lam: I'm sure you're going to tell us about it. Dr Greg Hundley: Right. So this study is from Professor Yan Li from Ruijin Hospital in Shanghai, Jiao Tong University School of Medicine. Gastrodia-uncaria granules Carolyn, is a mixture of Chinese herbs that dates back many years, I think thousands, and in this study was used in patients with masked hypertension. So in the study, patients with an office blood pressure of less than 140/90 millimeters of mercury, but a daytime ambulatory blood pressure of 135 to 150 millimeters of mercury systolic or 85 to 95 millimeters of mercury diastolic, were randomized one-to-one to receive the treatment of, and I'm going to abbreviate it, GUG versus placebo, 5 to 10 grams twice daily for four weeks. The primary efficacy variable was the change in daytime ambulatory blood pressure. Dr Carolyn Lam: Ah. (affirmative), so did it work? Dr Greg Hundley: Well, in their intention-to-treat analysis, daytime systolic-diastolic blood pressure was reduced by 5 and 3 millimeters of mercury in the GUG group, and 3 and 1.6 millimeters of mercury in the placebo group, respectively. The between group difference in blood pressure reductions was significant, 2.5 and 1.7 millimeters of mercury, and 24-hour blood pressure by 2 and 1.5 millimeters of mercury, but not for the clinic and nighttime blood pressures. The per protocol analysis in 229 patients produced similar results. Only one adverse event, sleepiness during the day was reported and no serious adverse events occurred. So Carolyn, a potentially inexpensive regimen found useful in China for patients with masked hypertension. To learn more of the results of this interesting study, listeners are suggested to review the article in this particular issue. Dr Carolyn Lam: Wow, interesting Greg. Okay. So from hypertension to CABG. Now we know that approximately 15% of saphenous vein grafts occlude during the first year after coronary artery bypass graft surgery, or CABG, despite aspirin use. So can ticagrelor added to standard aspirin improve saphenous venous graft patency at one year after CABG? Now this is the question that Dr ten Berg from St. Antonius Hospital from Nieuwegein in Netherlands, and colleagues sought to answer in the popular CABG trial, which was an investigator-initiated randomized double-blind placebo-controlled multicenter trial of 499 patients with one or more saphenous vein grafts, who were randomly assigned after CABG to ticagrelor or placebo added to standard aspirin. The primary outcome was saphenous vein graft occlusion at one year assessed with coronary CT angiography occurred in 10.5% of the ticagrelor group, versus 9.1% in the placebo group, so that's an odds ratio of 1.29, and it was not significant. The secondary outcome of one year saphenous vein graft failure, which was a composite of vein graft occlusion, revascularization, myocardial infarction in the myocardial territory supplied by the vein graft, or sudden death, well, that occurred in 14.2% of patients in the ticagrelor group, versus 11.6% in patients in the placebo group. Again, not a significant difference. Dr Greg Hundley: So Carolyn, a negative study? What's our take home here? Dr Carolyn Lam: In this randomized double-blind placebo-controlled trial, the addition of ticagrelor to standard aspirin after CABG did not reduce the rate of saphenous vein graft occlusions at one year. Now, this conclusion differs from some other studies that investigated this research question, and this is discussed in this editorial that you got to pick up. It's by Dr Goldman from the University of Arizona. Dr Greg Hundley: Wow, Carolyn. Great job. Well, we've got a couple more articles in this issue, and I'll start by describing a research letter by Dr Daviet regarding heparin-induced thrombocytopenia in COVID-19, and then Carolyn there's a second research letter from our own Torbjørn Omland regarding established cardiovascular biomarkers provide limited prognostic information in unselected patients hospitalized with COVID-19. And then finally, from Dr Chonyang Albert, a case series entitled, The Enemy Within: Sudden Onset of Reversible Cardiogenic Shock with Biopsy-Proven Cardiomyocyte Infection by SARS-CoV2. Dr Carolyn Lam: We've also got an ECG challenge by Dr Sreenivasan entitled, A Red Flag ECG, also known as, and have you heard of this, South African flag pattern. Okay, here's a hint. It's an important, but subtle ischemic ECG change. You got to look it up. There's an On My Mind paper by Dr Alexander on at risk of depriving patients’ life-saving cardiac surgery, and those are the implications of the ischemia trial for CABG. A Research Letter shared by Dr Susen entitled, Endotheliopathy is Induced by Plasma from Critically-ill Patients and Associated with Organ Failure in Severe COVID-19. And finally, in Cardiology News, Tracy Hampton reviews the most recent literature in top journals like Nature, Metabolism, Cell, Stem Cell, and Circulation Research. Wow. Bonanza issue. So cool, but I really want to hear about the different blood pressure patterns now. Let's go to our feature discussion, shall we? Dr Greg Hundley: Absolutely. Here we go. Well, listeners we are excited to get to this feature discussion to learn more about the use of ambulatory blood pressure measures, particularly those that are collected 24 hours and during the nighttime. We have with us, Dr Kazuomi Kario from the Jichi Medical University in Japan, and our own Associate Editor, Dr Wanpen Vongpatanasin from University of Texas Southwestern Medical Center in Dallas. Welcome to you both. And Kazuomi, could you start us off please and just describe some of the background that led you to perform this study? And what hypothesis did you want to address? Dr Kazuomi Kario: The old guidelines management of the hypertension and now recommend instead of the office blood pressure, now the ambulatory blood pressure management. So for example, the ABPN and also home blood pressure monitoring, but the 24-hour blood pressure reduction is very much important, all prefer the values, but also our hypothesis took on the 24-hour blood pressure quantity reduction, but also, we should normalize our circadian rhythm. Usually blood pressure reduced by 10 to 20% at night during the sleep compared to the daytime. But the other group, is exhibited and predicated known six bars and also is either higher at night during the nighttime period compared to the daytime. And also home blood pressure variability, that hurts blood pressure in the morning. So circadian rhythm normalization and also, I recreate blood pressure variability especially is more precise. It's important for the quality control over for the hypertension management. So my hypothesis is that blood pressure reduction, the other most blood pressure, and the normalized circadian rhythm, under agitate, to keep agitate among as such. All the three components I did try to optimize 24-hour blood pressure control, so I want to confirm our hypothesis. To optimize 24-hour blood pressure control consists of these three components, 24-hour pressure reduction, and the normalize circadian rhythm and the keeping the other keep such, it shouldn't be; I have, have you left your prevention or not? That's my hypothesis and background. Dr Greg Hundley: So with our 24-hour ambulatory monitoring evaluating in this study, do we have the normal dip during the evening? Do we have a rise associated with the circadian rhythm? What is the variability of the blood pressure over time? Tell us what study population, and how did you design this study to address your hypothesis? Dr Kazuomi Kario: This population is the hypertension patients, 90% or more on the out-patients who keep the adequate, the active daily readings, and they are medicated, or usually conventional hypertension medication is the effective to reducing the office blood pressure and they can. But the other hypotension treatment may not be sustained to be reducing the nocturnal blood pressure and next morning people are taking pills. So it may be that the picture of the nighttime blood pressure and the morning blood pressure. So our hypothesis targets is already mitigated hypotension patient, but we should find out control for the current hypotension treatment. It should be the nighttime and next morning.   Dr Greg Hundley: So we're addressing whether the efficacy of or any hypertensive medications are maintaining low blood pressures at night and avoiding a surreptitious rise in blood pressure when we wake up. So how many patients did you enroll and what were your study results? Dr Kazuomi Kario: The total study population number is 6,359 patients or enrolls. And we find out, compared to the daytime. Daytime also where the risk of the nighttime blood pressure other age, was more the precise this predictor of cardiovascular events. So, cardiovascular events consist of the atherosclerosis cardiac events consists of stroke and coronary artery disease. And also the nighttime blood pressure associated with the risk of the heart failure. And very interestingly, disrupted circadian rhythm, it rises at night higher during the nighttime compared to the daytime, it was independent of risks for the cardiovascular event, especially for the heart failure. So even after controlling for the daytime, even on the nighttime blood pressure, this pattern nighttime riser was an independent risk, so very interesting results. Dr Greg Hundley: So elevations of systolic blood pressure during nighttime, during sleep were associated with future atherosclerotic cardiovascular disease, as well as heart failure. And one more quick point, was there a particular magnitude of rise of that systolic blood pressure at night was important. And did you find similar results for men and for women? Dr Kazuomi Kario: Yes, similar results for men and the women. Theo other factor was age was increased. The almost the higher during the nighttime or other age of the rising pattern was 10 allowed during the nighttime compared to the daytime. Dr Greg Hundley: So even a 10% increase in systolic blood pressure at night relative to daytime was important for forecasting these adverse cardiovascular events. So Juan pen, can you help us take these results from this elegant ambulatory monitoring study and put those in the context of other study results that have evaluated 24 ambulatory monitoring of blood pressure? Dr Wanpen Vongpatanasin: I think the notion of nighttime blood pressure as the independent predictor of cardiovascular outcome has been shown in other cohort, but usually not this large magnitude, that is an international registry. I had call that in different countries around the world that demonstrate this. But again, like I said, it compiled from a smaller dataset, there's even fewer data sets in the United States. There's a cohort from Jackson Heart, but again, it's less than a thousand and most of other cohorts have looked at mostly a target organ level, not at the heart CV outcome. So I think this add to an important observation, and I think that the results from the nighttime it's similar, but extended from previously that look at individual outcome using a adjudicated data committee that also a very distinctive feature of the study that is a committee that look at this and look at a specific outcome rather than just a retrospective using the death index from different countries. The other part is slightly different perhaps, and they learn from reading it is the extreme dipping, also dropped a lot. Initially people think that it might be associated with the worst outcome, but even to me I wasn't sure what this mean, but in this study the most extreme dip, maybe not, not as much that shouldn't be worried as much compared to the actual nighttime blood pressure itself or not dipping itself. Dr Greg Hundley: Kazuomi what do you see as the next study that needs to be performed in this area of research? Dr Kazuomi Kario: Oh, it's the observational study of the current medical situations maybe kind of situations. So next step, we should focus on that nighttime blood pressure; regardless of the office and the daytime, so even there are controls, if we should target the nighttime blood pressure and the toxicity controls, organ damage should be decreased and the subsequent cardiovascular events should be decreased. So observational study targeting the nighttime blood pressure is the next topic. Dr Greg Hundley: And Wanpen do you have anything to add to that? Dr Wanpen Vongpatanasin:I'd like to see more large observational study from the US with the diverse population, because the salt consumption in Asia, particularly in Japan, are probably among the highest. So perhaps the nighttime blood pressure, it's confounded by high sodium and something, and we're not too far behind obviously, but it'd be nice to know what it means in the US. And obviously they're targeting nighttime blood pressure, it's the hot topic and that's by itself is probably another 30 minutes to an hour of discussion. But I think that that's very important area of research. Dr Greg Hundley: Listeners, what a really wonderful discussion. And in this study from Japan of over 6,000 individuals treated for high blood pressure, those with 24-hour monitoring and exhibiting a rise in systolic blood pressure during the nighttime was associated with future cardiovascular events and an increase in the risk of heart failure. Moving forward from these experts, performing additional observational studies to confirm these findings and other populations, and perhaps a randomized trial, trying to target therapeutic interventions that would lower nighttime blood pressure may be warranted. Thank you Dr Kario and Dr Vongpatanasin. We wish you a great week and we look forward to catching you on the run next week. This program is copyright The American Heart Association, 2020.

In this episode, I will talk with Adi Mazor Kario, an innovation expert and the founder of Invincible Innovation. We will talk about leading innovation and the connection between dealing with the unknown, mindfulness, and innovation. You can find more about Adi's activity here https://www.invincibleinnovation.com/

Real behavior change is fueled by emotion. How can designers leverage this universal truth to enhance their products and impact user journeys? Our guest today is Adi Mazor Kario, a design strategist and innovation expert. You’ll learn about emotion-based innovation, empathizing with users, trust-based onboarding, and applying emotional design in a variety of industries.Podcast feed: subscribe to https://feeds.simplecast.com/4MvgQ73R in your favorite podcast app, and follow us on iTunes, Stitcher, or Google Play Music.Show NotesWizard, Invincible Innovation, ExStrategy — Adi’s companies and projectsEpisode 119: Emotional Targeting with Talia WolfEpisode 173: Voice UX with Sina Kahen8 Things UX/UI Designers Can Learn From Steve Jobs — an article by Julia ZellEpisode 131: Design Sprint with Jonathan CourtneyInspire, Not Instruct: How We Do User Onboarding at Userlist — Jane’s articleHarnessing the Wind of Change — Adi’s upcoming bookChinese ‘Wind of Change’ proverbInvincible Innovation — Adi’s websiteConnect with Adi on LinkedIn and TwitterToday’s SponsorThis episode is brought to you by the new season of Wireframe — a podcast by Adobe about how UX can help technology fit into our lives. Whether you’re a designer or simply design-curious, you’ll learn how design intersects with the current world changes and hear from major leaders in the design and technology industries. Check out the show here, or just search for “Wireframe” in your favorite podcast app.Interested in sponsoring an episode? Learn more here.Leave a ReviewReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, please leave a review on iTunes. Here’s how.

Ya seas un streamer de Facebook, Twitch o un creador de contenido en general, esta entrevista te ayudará mucho y te llenará de motivación para continuar con tu sueño. Kario es una persona apasionada con los streams de video juegos, pero también es excelente dando consejos a esas personas que aspiran a crear su propio contenido, ¡así que motívate y dale play!Redes Sociales:FB:@aguaetuboIG:@aguaetubo

Interview of How to create a high-performance company with digital innovation. This interview "Anirvan in conversation with industry expert" is with Adi Mazor Kario, a well-known expert on digital innovation. Adi has helped a number of companies to create a high-performance future and lead in their market. She helps in accelerating product design and go-to-market strategy with the most experienced professionals in the field, using the most up-to-date methodologies only found in companies like Facebook, Google, Uber, or Airbnb. Adi Mazor Kario: https://www.linkedin.com/in/adimazorkario/ Contact Adi to know more about "Invincible Innovation Program" ------- The host of the interview is Anirvan Sen, CEO - Fifth Chrome, https://www.linkedin.com/in/anirvansen/ Struggling with your digital strategy? Let us set up a "FREE" 30-min ideation call with Anirvan at https://calendly.com/anirvan-sen/30min ------- This interview is part of a series run by Fifth Chrome, a firm that advises businesses to reinvent themselves through digital innovation and get exceptional growth.

Dedicamos este episodio a algunos talentos musicales jóvenes que nos encantan. Repasamos las influencias de bandas como Alabama Shakes, Kario, Daughter o Nothing But Thieves, recuperando la música de PJ Harvey, Nina Simone o Nick Cave. Un auténtico repaso a la historia reciente del rock y el pop occidental. ¡Sube el volumen!

Award-winning actor, writer, producer, musican, legend Kario Salem has had two successful careers-- and his share of life-changing challenges—and now, he’s decided to take the biggest risk of his life and trade in the sure money and stability...to go hard after the passion that he’s had to push down and try to ignore for decades. Listen up and come away fired up to never ignore your passion, no matter what the people around you might say.KARIO on InstagramKARIO Video: A Piece of MeKARIO on SpotifyKARIO on iTunesFEATURED ARTISTSJules De Balincourt Mind-blowing painterThe National Mind-blowing rock bandThe War on DrugsFather John MistyEdward Sharpe & the Magnetic ZerosVampire Weekend Subscribe to Nice Work! on Apple Music http://bit.ly/NiceWorkPodcast Subscribe to Nice Work! on Stitcher http://bit.ly/NiceWorkStitcher Subscribe to Nice Work! on Spotify http://bit.ly/SuperNiceWork Subscribe to Nice Work! on Google Play http://bit.ly/NiceWorkGoogle Subscribe to Nice Work! on Tune In http://bit.ly/NieWorkTuneIn Subscribe to Nice Work! on Deezer http://bit.ly/NiceWorkDeezer   Subscribe to Nice Work! on YouTube http://bit.ly/NiceWorkYouTube

גלעד פגש את עדי מזור קריו והם דיברו על תהליך הדזיין ספרינט, המקורות מעולם הדזיין טינקינג, איזה בעיה הוא נועד לפתור, השלבים השונים בכל תהליך ומתי הוא כלי שיכול לשרת מנהלי מוצר ___
 מגיש בפרק: גלעד לבנת 
עריכת סאונד והלחנה: מיכאל ינטיס

Dr Carolyn Lam:                                Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the Journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center, and Duke National University of Singapore. Dr Greg Hundley:                             And I'm Greg Hundley, associate editor as well, at Circulation, and director of the Pauley Heart Center in Richmond, Virginia at VCU Health. Carolyn, this issue, we've got a super-exciting interaction to follow related to SGL2 inhibitors on 24-hour ambulatory blood pressure in African-Americans, something used to treat diabetes, and maybe a positive effect on blood pressure, but more to come on that. Now, Carolyn, you're also planning to discuss some results from another SGL2 study. Dr Carolyn Lam:                                You bet. This time, I'm taking you to Japan for the results of the SACRA study which stands for SGLT2 Inhibitor and Angiotensin Receptor Blocker Combination Therapy in Patients with Diabetes and Uncontrolled Nocturnal Hypertension and this is from Dr Kario and colleagues from Tochigi in Japan. It's a multi-centered, double-blind parallel study of 132 non-obese older adults with type 2 diabetes and uncontrolled nocturnal hypertension, receiving stable antihypertensive therapy, including angiotensin receptor blockers, who were then randomized to 12 weeks' treatment with empagliflozin 10 milligrams once daily or placebo. Clinic blood pressure was performed at baseline in weeks four, eight and 12. Twenty-four hour ambulatory blood pressure monitoring was performed at baseline and week 12 and morning home blood pressure was determined for five days before each visit. The primary efficacy endpoint was changed from baseline in nighttime blood pressure. Dr Greg Hundley:                             So, what did they find, Carolyn? Dr Carolyn Lam:                                Well, empagliflozin significantly reduced nighttime systolic blood pressure versus the baseline. The reductions in daytime 24-hour morning, home, and clinic systolic blood pressure at 12 weeks with empagliflozin was also greater than placebo. Between group differences in body weight and glycosylated hemoglobin reductions were significant, but small and the changes in antihypertensive medication during the study also did not differ significantly between the groups. Dr Greg Hundley:                             Very good. Well, I'm going to switch gears and talk also on the same theme of sugar and diabetes and evaluate the long-term consumption of sugar-sweetened and artificially-sweetened beverages and the risk of mortality in U.S. adults. This is a study by Vasanti Malik from the Harvard School of Public Health. Now, as you know, in epidemiologic studies, intake of sugar-sweetened beverages has been associated with weight gain, a higher risk of type 2 diabetes, coronary heart disease and stroke, but to date, few studies have examined the association between sugar-sweetened beverages and intake and mortality. All right, Carolyn, I'm going to give you a quiz now. Here's the first question. Dr Carolyn Lam:                                What? Dr Greg Hundley                               That's right, sugar-sweetened beverages are the single largest source of added sugar in the U.S. diet, true or false? Dr Carolyn Lam:                                I'm going to guess true. Dr Greg Hundley:                             Okay, so all those consumption of sugar-sweetened beverages in the United States has decreased in the past decade. National survey data show a slight rebound in consumption in recent years among adults in many age groups. With the average equivalent being, multiple choice, 2%, 6.5% or 10% of our total energy requirements? Dr Carolyn Lam:                                Oh, my goodness. One of the higher ones. I'm just going to go in the middle, 6.5. Dr Greg Hundley:                             Excellent, good choice, you're a good multiple-choice taker, 6.5%. So, among younger adults, sugar-sweetened beverages contributed. They're a little bit higher, 9.3% of the daily calories in men and 8.2% in women in the United States. Now, how about other parts of the world, particularly developing countries? The intake of sugar-sweetened beverages, is it dropping, is it flat or is it rising dramatically? Dr Carolyn Lam:                                Sorry, Greg, but that one's too easy. It's definitely rising. Dr Greg Hundley:                             Yup, you got that right. Dr Carolyn Lam:                                I live in those other developing countries, so I've seen so. Dr Greg Hundley:                             And it's really thought due to widespread urbanization and beverage marketing. So, now we've got an alternative, artificially-sweetened beverages. And they're often suggested as alternatives to sugar-sweetened beverages and intake levels have increased of these alternative sweeteners in the United States. So, next question. Are the artificially sweetened beverages a better alternative to sugar--sweetened beverages in regard to cardiovascular or all-cause mortality? Dr Carolyn Lam:                                Yikes. Okay, so Greg I'm afraid to guess on this one because I have to admit I sometimes, with a sweet tooth, like to take these alternative beverages. I think you're going to be telling us. Dr Greg Hundley:                             Well, we don't know. Most of the data in this area is from research and comes from associative analyses utilizing longitudinal cohorts and some studies suggest yes, some studies, no. For example, one in the elderly suggested artificially-sweetened beverages, but not sugar-sweetened beverages were associated with adverse events, but critiques indicated that finding may have related to reverse causation because the elderly patients were switching from sugar-sweetened to artificially-sweetened beverages. So, where are we now? Well this study, in our Journal, examined the associations between the consumption of sugar-sweetened beverages and artificially-sweetened beverages with the risk of total and cause-specific mortality among 37,716 men from the Health Professionals Follow-up Study between 1986 and 2014 and 80,647 women from the Nurse's Health Study from 1980 to 2014, who were free from chronic diseases. Dr Carolyn Lam:                                Wow, that's a huge combined cohort. So, come on, what were the results? Dr Greg Hundley:                             So, the researchers found after adjusting for major diet and lifestyle factors, consumption of sugar-sweetened beverages was associated with a higher risk of total mortality and cardiovascular mortality and cancer mortality and, thus, the results provide further support for the recommendations and policies to limit intake of sugar-sweetened beverages and to consume artificially-sweetened beverages in moderation did improve overall health. Now, what were the results from artificially-sweetened beverages? Well, they were associated with total and cardiovascular disease mortality in the highest intake category only. So, those consuming large amounts of those daily, but only in the cohort of women from the Nurse's Health Study, not from the men in the Health Professionals Follow-up Study. Artificially-sweetened beverages were not associated with cancer mortality in either cohort. So, moving forward, the positive association between high intake of artificially-sweetened beverages and total and cardiovascular disease mortality observed among women requires more study and further confirmation and also, we might consider that even though artificially-sweetened beverages could be used to replace sugar-sweetened beverages among habitual sugar-sweetened beverage consumers, higher consumption of the artificially-sweetened beverages would probably be discouraged. Finally, policies and recommendations should continue to call for reductions and limits on sugar-sweetened beverages intake and also address alternative beverage offerings with an emphasis on our favorite, water. Dr Carolyn Lam:                                Sweet, Greg! Or maybe not so sweet. Oh, goodness. All right, well my paper deals with related, but not related perhaps, but talking about ketone body, 3-hydroxybutyrate and the cardiovascular effects of treatment with this ketone body in chronic heart failure and this is from corresponding author, Dr Nielsen from Aarhus University Hospital in Denmark and his colleagues. Now, they performed a series of studies. In the first 16 chronic HFrEF patients were randomized in a crossover design to three hours' infusion of 3-hydroxybutyrate or placebo and monitored invasively with a Swan-Ganz catheter and studied with echocardiography and they found that infusion of 3-hydroxybutyrate increased cardiac output by two liters per minute or 40% with an absolute improvement in left ventricular ejection fraction of 8%, and the observed defects were accompanied by vasodilation with a resultant stable systemic and pulmonary blood pressure. Now, in the second part of the study, they studied eight HFrEF patients examined at increasing infusion rates of 3-hydroxybutyrate and they found a dose response relationship with a significant increase in cardiac output. And, finally, they studied 10 HFrEF patients and 10 age-matched volunteers, randomized in a crossover design to a three hour infusion of 3-hydroxybutyrate or placebo and they looked this time at myocardial external energy efficiency and oxygen consumption using 11-carbon acetate PET and what they found was 3-hydroxybutyrate increased oxygen consumption without altering myocardial external energy efficiency. The response did not differ between HFrEF and age-matched volunteers. Dr Greg Hundley:                             Wow, Carolyn, there was a lot of data in that study. So, what's your main take home? Dr Carolyn Lam:                                In summary, 3-hydroxybutyrate, this ketone body, demonstrated dose-dependent beneficial cardiac and hemodynamic effects in patients with heart failure reduced ejection fraction without deteriorating mechano-energetic coupling and without causing any safety issues. And what's significant is that this opens the door to modulating circulating 3-hydroxybutyrate as a novel treatment option in patients with heart failure. Dr Greg Hundley:                             Right, Carolyn, so I've got an interesting study from the world of basic science that's looking at the role of potassium channels as novel molecular targets and bradyarrhythmia’s and even, perhaps, in atrial fibrillation. This is from Yoshihiro Asano from Osaka University in Japan. So, the acetylcholine activated potassium channel is expressed in the sinus node, atrium, and atrioventricular node and contributes to heart rate slowing triggered by the parasympathetic nervous system. So the potassium, activated potassium channel is a heterotetramer of 2 inwardly rectifying potassium channel proteins encoded by two genes, KCNJ3 and KCNJ5, respectively. Dr Carolyn Lam:                                Okay, so what did this study show? Dr Greg Hundley:                             What it showed is a selective potassium acetylcholine channel blocker effectively inhibited a mutant potassium channel and up-regulated heart rate and bradyarrhythmias using a zebra fish model. And this is really interesting, Carolyn, because two conclusions are worth considering. First, future studies could determine the prevalence of bradyarrhythmias associated with dysfunctional mutation in this potassium channel. And, second, results raise the possibility that pharmacologic blockade of this channel might serve as a therapy for increasing heart rate and be especially beneficial for bradyarrhythmias in patients with gain of function mutations in the channel and, therefore, genetic testing for KCNJ3 and KCNJ5 in patients with bradyarrhythmias may provide a drug treatment option in lieu of an invasive surgical implantation of a pacemaker. Dr Carolyn Lam:                                Fascinating! Thanks, Greg. What a great issue and now onto an even greater feature discussion. Dr Greg Hundley:                             Welcome, everybody, to the second part of this interview. We've got a very exciting paper to discuss with you. Remember this is our backstage pass to Circulation and we've got today, Keith Ferdinand from Tulane University in Louisiana and our Associate Editor, our hypertensive expert, Dr Wanpen Vongpatanasin from the University of Texas Southwestern Medical School in Dallas. We're going to be discussing the anti-hyperglycemic and blood pressure effects of empagliflozin in African-Americans with type two diabetes and hypertension. Keith, we're going to start with you. What was your hypothesis for this study? Who's the study population? Review a little bit about your design and, importantly, what were your results? Dr Keith Ferdinand:                         Well, my hypothesis was that one of the new classes of medications, the SGLT2 inhibitors, which have a mild diuretic effect and a mild natriuretic effect, may have benefits in self-described African-Americans in not only controlling glucose, but also controlling hypertension. These medicines are approved, of course, as medications for type 2 diabetes, but we had seen in some earlier trials that did not include self-defined African-Americans, that there may be a blood pressure effect. We know that diabetes is higher in blacks, almost twice that seen in the general population and, of course, hypertension and uncontrolled hypertension is disproportionate. So, here's a medication that may be even more beneficial in that population and we wanted to study it. Dr Greg Hundley:                             And tell us a little bit about who was in the study and what was your design? Dr Keith Ferdinand:                         The design was to be a placebo-controlled randomized trial using empagliflozin starting at 10 milligrams and force-titrating to 25 milligrams versus placebo on the background of conventional anti-hypertensive agents. Everyone was on one or more anti-hypertensive agents. We used the gold standard for blood pressure control with 24-hour ambulatory blood pressure and that was the means by which patients entered the study, although the primary endpoint was changed in hemoglobin A1c, we actually designed and powered the study to see if there would be a change in blood pressure. Additionally, we looked for changes in weight, losing calories with the effects of the SGLT2 inhibitors with glycosuria has translated in some preliminary trials to weight loss. So, this was a study looking at a population. Most of them had diabetes for approximately nine to 10 years, 59 years of age, definite hypertension, obesity, a high risk population, to see if a new class of medications would be beneficial. Dr Greg Hundley:                             And what did you find? Dr Keith Ferdinand:                         Fortunately, we did find an effect. It did lower the primary endpoint of a change in hemoglobin A1c, but remember it was powered also by blood pressure effect and fortunately, we did see that both with the ambulatory and clinic blood pressure, both at 12 weeks and 24 weeks. The clinic blood pressure was a trend, but the ambulatory blood pressure was positive at 12 weeks and both had a strong difference in terms of confidence intervals for blood pressure lowering. About five millimeters of mercury at 12 weeks and up eight millimeters of mercury at 24 weeks for the change in ambulatory blood pressure which, in a large population would translate into a significant blood pressure lowering, the hemoglobin A1c reduction was also significant. But, although that was the primary endpoint, my concern is as a cardiologist and cardiovascular specialist. Dr Greg Hundley:                             And what dose did you select? Did you have to up-titrate this at all and, finally, were there any side effects? Dr Keith Ferdinand:                         You know, with the SGLT2 inhibitors, you have an effect both in terms of glycosuria, some osmotic diuresis and some natriuresis, and with the loss of body weight. But the change in body weight really wasn't that much, about 1.2 kilos and the change in blood pressure was discordant with the change in body weight. So, we think that the effects in blood pressure may be from extended diuretic effect, but it may also be from effects on endothelial function that are outside those significantly related to diuresis, per se. Because you're urinating glucose, glycosuria, you would expect the potential for superficial infections, mycotic infections and that was seen. The rates were not prohibitive and not dissimilar to what's been seen in other studies. So, overall, the drug was well-tolerated. It did not have any significant adverse effects outside of a few mycotic infections, which are basically superficial fungal infections and that's been seen in other uses of the SGLT2 inhibitors, but nothing that I think would be unusually disturbing in this population. Dr Greg Hundley:                             Outstanding. So, Wanpen, going to switch over to you and ask you to help us put this in the context of treating African-American men, women with hypertension. How do we think about using this new finding? How would we integrate it with other therapies that these individuals already might be taking? Dr Wanpen Vongpatanasin:         Sure, so I think that this study is very intriguing and interesting that empagliflozin to me actually had more prominent benefit on lowering 24-hour blood pressure than the previous study that the true analysis showed the effects of 24-hour blood pressure is much less or almost half of four to five millimeters of mercury and that could be that this was not that significant in African-Americans and maybe this drug is particularly effective and, as you know, African-Americans tend to have more salt sensitive form of hypertension and I wonder if that could explain the results, but I think it's very encouraging because this drug class approved for treatment of diabetes and medication. African-American have higher blood pressures than other ethnic groups and having diabetes makes them prone to having more resistant hypertension. In this particular trial, almost 40% of the patients enrolled is already taking three or more antihypertensive medications, so adding this on top and having that benefit is as good as adding spironolactone, for example, and I didn't see from the manuscript, how many patients are taking spironolactone already, but I would be curious to see that, as well. But I think that is something that physicians should think about and this drug is already FDA-approved for treating diabetes, so if you have a patient with difficult to control blood pressure and already needed something for diabetes, this could make a lot of sense to use it. Dr Greg Hundley:                             Keith, do you have any thoughts on Wanpen's comment regarding the use of spironolactone in the study population? Dr Keith Ferdinand:                         No, I don't have those specific data available at the time that we're speaking now, but that's certainly something that I will attempt to look at the database and get more information. But, I think Wanpen is absolutely right. If you look at some of the previous studies, for instance, EMPA-REG, the major outcomes trial that led to the indication of a decrease in cardiovascular death and heart failure, the blood pressure lowering wasn't that robust, maybe 4/2, but here we saw at week 24, 10 millimeters of mercury of blood pressure reduction and if you placebo subtract, which is what I mentioned in my first comments, you're talking about 8 to 8.5 millimeters of mercury reduction and that's a significant reduction, especially for ambulatory blood pressure measurement. Dr Greg Hundley:                             Absolutely. So, I'm going to go with each of you separately, but taking this manuscript and this work that Keith, you've performed, we'll start with you. What do you think of the next steps in the research in this area, both from the perspective of using this family of agents in individuals with both diabetes and hypertension? Dr Keith Ferdinand:                         What I would hope in the future is another outcome study is done with an SGLT2, any numbers of that class, that they particularly target enough African-Americans to see if this robust blood pressure reduction not only is found again, but also translates to decreased cardiovascular events. You know, NHLBI, for instance and ALLHAT, selectively over-represents African-Americans. They had 35% African-Americans in ALLHAT and the reason for that is you have a population that has a disproportionate degree of hypertension and a disproportionate degree of associated cardiovascular disease and renal disease, so you want to make sure that any medication that's been shown to be effective is effective in the higher risk population. So a future outcome study, regardless of whether they're renal-based or related to heart failure, I hope will target an increased population of blacks to see some of the robust reduction we have, translates in cardiovascular events. My suspicion is that self-defined African-American versus a genetic factor, describes the phenotype of patients who tend to be more obese, have more salt sensitivity, perhaps subclinical kidney disease and will respond to a medication that has some diuretic natriuretic effects and effects with endothelial dysfunction and sympathetic discharge. Dr Greg Hundley:                             Very good, well I heard sympathetic discharge. Wanpen, any comments there? That's your area. Dr Wanpen Vongpatanasin:         I think that definitely needs to be studied. To my knowledge, there was only one small study that published that tried to measure sympathetic nerve activity directly, but unfortunately that study after a very short-term treatment for like four or five days, so I’m sure that there will be more studies to come and also hope that the future study will shed light on any particular markers with surrogate that will identify patients that will respond better, for example, PATHWAY-2 trials that were done to test the effects of spironolactone on resistant hypertension they found that the lower the reading, the more likely you can have better response to Aldactone and I wonder if this might apply to empagliflozin and be something else. I think the fact that the blood pressures continued to decline from the week 12 to week 24 is very, very interesting when the body weight effect doesn't necessarily go down much further. This really tells us there's something else beyond weight and perhaps glucose that would explain this. Dr Greg Hundley:                             Very good. Well, I certainly want to thank you both for this outstanding discussion. Keith, we want to thank you for bringing this manuscript to Circulation and identifying this new application for this therapy in African-Americans. Wanpen, thank you also for your time and comments. On behalf of Carolyn and myself, we really appreciate you listening. Have a great week and we look forward to seeing you next week. Dr Carolyn Lam:                                This program is a copyright of American Heart Association 2019.  

Kario Salem directs "Stand Down" with Billy Bob Thornton, along with co director Dana Tynan. Kario chats about the making of this film, as well as another film that he wrote, one of my favorites, "The Score" with Robert De Niro, Edward Norton, and Marlon Brando.

Valdo Gedgaudo nuo 2013 metų jau nėra tarp mūsų, mirė palaužtas ankstyvos mirties. Šįkart atsiversime trečią jo poezijos rinkinį „Kario šešėlis“, kuris išėjo 2009 m. Poeto vaizduojamas pasaulis – sklidinas žeidžiančių prieštaravimų. Lyrinis herojus pasmerktas pralaimėti, bet pralaimi ramiai ir stoiškai. Valdo Gedgaudo balsas iš 2010 m. įrašo.

Valdo Gedgaudo nuo 2013 metų jau nėra tarp mūsų, mirė palaužtas ankstyvos mirties. Šįkart atsiversime trečią jo poezijos rinkinį „Kario šešėlis“, kuris išėjo 2009 m. Poeto vaizduojamas pasaulis – sklidinas žeidžiančių prieštaravimų. Lyrinis herojus pasmerktas pralaimėti, bet pralaimi ramiai ir stoiškai. Valdo Gedgaudo balsas iš 2010 m. įrašo.

Wednesday is upon us again, and we're continuing our quest to discuss each game on the NES Classic. In this episode we're talking about Mario Bros. No, not that Mario Bros., the original Mario Bros. Y'know, the 1983 arcade platformer that was ported to the NES. It's been a snowy week here at TADPOG HQ, so there are a few snow stories. We also decide that it's important to know your sexual lemons. We learn about Kario, there is a celebrity twins quiz, and we take some calls.  Continue reading → The post Ep. 436 – Mario Bros. appeared first on TADPOG: Tyler and Dave Play Old Games.

Tuskaisesta nuoresta naisesta kasvoi säteilevä monen alan osaaja. Irma unelmoi näyttelijän ammatista. Se jäi haaveeksi, mutta ura urkeni kumminkin teatterin ja elokuvan alalta. Hyvä näin, sanoo Irma. "Tuleva aviomieheni heitti kruunaa ja klaavaa Suomeen-lähdöstä. Kolikko päätti, että hän hyppää laivaan. Tapasimme, ja muutin Ruotsiin.    Irma Kario kertoo virstanpylväistä työuransa varrella: 1971 1975 Toimin sihteerinä ympäristönsuojeluhallinnossa, ensin organisaatio oli Ympäristönsuojelun lautakunta, sitten siitä kehittyi ympäristönsuojelun osasto sisäministeriössä ja tästä ajasta olin vuoden 1974 Itämeren suojelukomitean sihteerinä. Suomi toimi komitean päämiehena ja järjestimme konferensseja Hangossa ja Hanasaaressa. Niihin kokoontui tutkijoita ja päätöksentekijöitä kaikista Itämeren valtioista. Jännittävä kokemus ja elämys näiden vuosien aikana oli osallistuminen YK:n Ympäristänsuojelukonferenssiin Tukholmassa 1972. Silloin en voinut aavista että Tukholmasta tulisi kotikaupunkini.   1975-1978 Suomenruotsalaisen dokumenttielokuvayhtiön Epidemin toimitusjohtaja. Epidem oli erikoistunut Etelä-Amerikan maiden, erityisesti Chilen, kuvaukseen ja teki usein yhteistyötä SVT:n kanssa. Minun tehtäväksi lankesi hallinnon ja taloudenhoidon lisäksi Camilla Mickwitzin luomien animaatioelokuvien tuottaminen.   1978 Muutto Tukholmaan   1978-1979 Johan Haglebäckin toteuttaman  animaatioelokuvan Vem ska trösta knyttet? tuotantotehtävät, mm kontaktit Tove Janssonin kanssa.   1979-1985 Dramatiska Institutetin teatteriosaston kurssisihteerinä. Näiden vuosien aikana opin tuntemaan koko Ruotsin  teatterimaailman. Toimin myös silloisen Nordiska Scenskolerådetin hallituksen jäsenenä. Siihen aikaan oli pohjoismaisilla yhteistyöprojekteilla ihan toinen rooli kuin tänään. Joka kevät järjestettiin koulujen välisiä tapaamisia eri maissa. Ja näin myös kontaktit Suomen Teatterikorkeakouluun syntyivät ja vahvistuivat.   1985-1988 Folkoperan markkinoija ja tuotantoassistentti. Dramatiska Institutetin teoreettisten vuosien jälkeen halusin kokea näyttämötaiteen tekemistä ihan konkreettisesti. Ja niin tämä mahdollisuus putkahti esiin Folkoperan muodossa. Näiden vuosien aikana oli ohjelmistossa Madame Butterfly, Taikahuilu, Turandot ja Lionardo. Asuin Folkoperan naapurikorttelissa ja olin vastuussa siitä että koko orkesteri oli aina paikalla esitysten alkaessa. Juoksin edestakaisin enkä uskaltanut alottaa illan viettoa ennenkuin esitys klo 19.00 oli alkanut.   1988-1992 asuin Helsingissä   1989-1991 Svenska Teaterin markkinointisihteerinä. Silloinen teatterinjohtaja Georg Dolivo, jonka tunsin jo entuudestaan, järjesti minulle työpaikan ja siitä olin todella iloinen ja kiitollinen   1991-1992 Teatteri Viiruksen tuottajana. Heti Suomeen muuton jälkeen toimin Viiruksen hallituksen jäsenenä ja kun päätimme että nyt on teatterin aika hankkia ensimmäistä kertaa tuottaja niin tehtävä lankesi aika luonnollisesti minulle. Uskomattoman huimat, antoisat ja unohtumattomat ajat seurasivat. Teatteria johtivat silloin Johan Storgård ja Mats Långbacka. Teatteri toimi silloin Rajasaaressa ja kesällä teimme Shakespearen tuotantoja Vasikkasaaressa Helsingin edustalla Ralf Långbackan ohjauksella.   1993-2003 Perustin oman tuotantoyhtiön Kario Kultur. Näiden vuosien aikana tein seuraavanlaisia projekteja: Sain pian Ruotsiin paluun jälkeen tehtäväksi tuottaa Marionetteaterin kansainvälisen, aikuisille suuntautuvan nukketeatterifestivaalin. Sen kautta tutustuin huimiin kansainvälisiin tekijöihin ja ne kontaktit johtivat sarjaan festivaaleja jotka saivat nimeksi Non Stop Puppets. Kun Tukholma oli Euroopan kulttuuripääkaupunki 1998 järjestin tämän festivaalin Kapunginteatterissa, silloin yhteistyössä Kaupunginteatterin Långa Näsanin kanssa. Teatterin kaikki näyttämöt täyttyivät silloin aikuisten nukketeatterista. Samoin järjestin uuden Non Stop Puppets-festivaalin Helsingin ollessa kulttuurpääkaupunkina 2000, joka sitten Helsingin jälkeen siirrettiin Tukholmaan. Järjestin suomenruotsalaisten teatteriryhmien, Viiruksen, Mars-teatterin ja Klockriketeaterin vierailuesityksiä Tukholmassa. Toimin muusikkojen Ale Möllerin ja Lena Willemarkin ja kaikkien heidän erilaisten kokoonpanojensa managerina/tuottajana, kuten esim. Enteli, Frifot, Stockholm Folk Big Band, Ale Möller Band. Tallissani oli niin kansanmusiikka, maailmanmusiikkia kuin jazzia.   2003-2012 Uuden Teatterin toiminnanjohtaja. Vuonna 2005 teimme yhteistyösopimuksen Teater Västmanlandin kanssa joka merkitsi sitä, että saimme kaikki teatterin resurssit, ts. tilat, tekniikan ja henkilöstön käyttöömme korvauksetta sitä vastaan että esityksemme tulivat mukaan teatterin omaan tilastoon. Meillä oli silloin Tukholman toimisto RSKL:n tiloissa Bellmansgatanilla ja tuotannot toteutettiin siis Västeråsissa. Haastattelija: Soili Huokuna.

World champion professional juggler Adam Kario joins us to talk about his Ohio upbringing, his Greek roots, and traveling the world as an entertainer.

Join Alex and Tigs as they discuss the 3DS, Ryse: Son of Rome, Earth Defense Force 2025, Threes, Mr Driller, TxK, Styder, Journal, Kario, Ultimate Flirt Off, Consensual Torture Simulator and more on this episode of Griefed! Recorded on February 26th 2014.

Aamun vieras on Uuden teatterin toiminnanjohtaja Irma Kario. Puhumme hänen kanssaan niin teatterivaihdosta kuin Uuden teatterin syksyn tarjonnasta. Uusi teatteri ja Irma Kario ovat olleet mukana aluasta asti, kun viisi vuotta sitten Ruotsin ja Suomen välistä teatterivaihtoa rydyttiin elvyttämään. Vuosittain Tampereen teatterikesän yhteydessä teatteriväki suunnittelee uusia projekteja. Ruotsista tapaamisessa ovat mukana Riksteatern ja Uuden teatterin toiminnanjohtaja Irma Kario. Suomessa teatterivaihtoa halutaan nyt kehittää uuteen suuntaan ja mukaan on tullut uusia yhteistyöteattereita, kertoo Kario kertoo. Riitta Niemi haastattelee.